In this issue:
ICH and in-hospital mortality for DOACs vs. other oral anticoagulants
Effectiveness and safety of anticoagulants for cancer-associated VTE
Mechanisms of thrombosis induction by antiphospholipid antibodies
Antiphospholipid antibodies and recurrent thrombosis after a first VTE
Altered plasma clot properties increase recurrent DVT risk
Gene therapy for transfusiondependent β-thalassaemia
AAV-5/FIX gene therapy for haemophilia B
Oral factor Xa inhibitor vs. LMWH in cancer-associated VTE
Improving haemostasis in haemophilia by targeting protein S
Recanalisation and long-term neurological outcomes after CVT
Please login below to download this issue (PDF)